Short Interest in Sutro Biopharma, Inc. (NASDAQ:STRO) Declines By 85.9%

Sutro Biopharma, Inc. (NASDAQ:STRO) saw a large decline in short interest in the month of December. As of December 15th, there was short interest totaling 560,264 shares, a decline of 85.9% from the November 30th total of 3,977,435 shares. Based on an average trading volume of 139,822 shares, the days-to-cover ratio is currently 4.0 days. Approximately 7.0% of the shares of the company are short sold. Approximately 7.0% of the shares of the company are short sold. Based on an average trading volume of 139,822 shares, the days-to-cover ratio is currently 4.0 days.

Wall Street Analysts Forecast Growth

A number of research firms have commented on STRO. Weiss Ratings restated a “sell (d-)” rating on shares of Sutro Biopharma in a research report on Monday. Wall Street Zen lowered shares of Sutro Biopharma from a “hold” rating to a “sell” rating in a research note on Saturday, November 8th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of Sutro Biopharma in a report on Wednesday, December 17th. Wedbush reaffirmed a “neutral” rating and set a $100.00 price target (up from $20.00) on shares of Sutro Biopharma in a research note on Tuesday, December 2nd. Finally, HC Wainwright lifted their price target on Sutro Biopharma to $10.00 and gave the company a “neutral” rating in a research report on Monday. Two analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $33.60.

Sutro Biopharma Stock Performance

Sutro Biopharma stock opened at $10.63 on Friday. The firm has a market cap of $90.42 million, a price-to-earnings ratio of -0.41 and a beta of 1.61. Sutro Biopharma has a 1 year low of $5.23 and a 1 year high of $21.50. The firm’s 50 day moving average price is $9.57 and its two-hundred day moving average price is $8.82.

Sutro Biopharma (NASDAQ:STRO) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($0.67) EPS for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.25). The company had revenue of $9.69 million for the quarter, compared to analyst estimates of $10.14 million. Sutro Biopharma had a negative net margin of 206.77% and a negative return on equity of 852.70%. As a group, equities analysts predict that Sutro Biopharma will post -2.92 EPS for the current fiscal year.

Insider Activity

In other Sutro Biopharma news, Director Connie Matsui purchased 5,000 shares of the stock in a transaction dated Wednesday, October 15th. The shares were bought at an average cost of $8.00 per share, with a total value of $40,000.00. Following the completion of the acquisition, the director owned 5,000 shares of the company’s stock, valued at approximately $40,000. This trade represents a ? increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders acquired a total of 11,175 shares of company stock valued at $89,598 over the last ninety days. Corporate insiders own 3.60% of the company’s stock.

Institutional Trading of Sutro Biopharma

A number of hedge funds have recently bought and sold shares of the company. Invesco Ltd. lifted its position in shares of Sutro Biopharma by 137.8% during the 1st quarter. Invesco Ltd. now owns 92,139 shares of the company’s stock worth $60,000 after purchasing an additional 53,390 shares during the last quarter. Nuveen LLC bought a new position in Sutro Biopharma in the 1st quarter worth approximately $189,000. Affinity Asset Advisors LLC bought a new position in Sutro Biopharma in the 1st quarter worth approximately $490,000. State of Wyoming acquired a new position in shares of Sutro Biopharma during the first quarter worth approximately $62,000. Finally, Velan Capital Investment Management LP boosted its position in shares of Sutro Biopharma by 3,333.3% in the first quarter. Velan Capital Investment Management LP now owns 1,030,000 shares of the company’s stock valued at $670,000 after acquiring an additional 1,000,000 shares during the period. 96.99% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Sutro Biopharma

Here are the key news stories impacting Sutro Biopharma this week:

• Positive Sentiment: HC Wainwright sharply raised several near?term earnings estimates (notably FY2025 EPS from ($22.00) to ($2.85) and meaningful upgrades to multiple 2026 quarterly forecasts), signaling an improved near?term outlook from that analyst. The firm kept a $10 price target. Price Target Raised to $10.00
• Positive Sentiment: Short interest plunged (~85.9% month?over?month to ~560k shares as of Dec. 15), reducing potential short?squeeze risk and lowering selling pressure from short sellers — typically a supportive technical factor for the stock.
• Neutral Sentiment: HC Wainwright maintained a “Neutral” rating despite the model changes, so the firm’s view remains cautious even after the estimate revisions; the $10 target is constructive but not a buy recommendation.
• Neutral Sentiment: Some reporting contains inconsistent short?interest figures (an entry showing 0 shares and 0 days to cover), suggesting at least one data anomaly; rely on the verified 560k number above rather than the 0 figure.
• Negative Sentiment: HC Wainwright cut out?year profit forecasts for FY2028 and FY2029 (EPS estimates worsened vs. prior), which implies softer long?term profitability assumptions and could cap upside if longer?term prospects are seen as weaker.

Sutro Biopharma Company Profile

Sutro Biopharma, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel biologic drug candidates in the fields of oncology and immunology. The company leverages a proprietary cell-free protein synthesis platform, XpressCF™, to design and produce complex, multi-specific proteins that include antibody-drug conjugates, bispecific antibodies, and cytokine fusion proteins. This platform enables rapid generation and optimization of protein therapeutics that may not be feasible with traditional cell-based expression systems.

Founded in 2003 and headquartered in South San Francisco, California, Sutro Biopharma has built a pipeline of immuno-oncology candidates in various stages of preclinical and clinical development.